Additionally, constipation can be an issue, affecting roughly 30% of people during early GLP-1 treatment, largely due to reduced fluid and fiber intake
UK Evidence & Safety Weight loss injections, particularly GLP-1 receptor agonists like semaglutide (Wegovy) and liraglutide (Saxenda), are increasingly prescribed in the UK for obesity management
For example: Pharmaceutical Technology reports, In the US, semaglutide prices have increased by 30% over the past yea r. That kind of rapid inflation changes how clinics price access, and it makes short-term scarcity and long-term affordability separate problems
Store the pen in the refrigerator
If you are obese or overweight, you could be the right candidate for this weight loss therapy
Hepatology 21 , 740745